Charles River boosts CRO chops with $800M deal for MPI

Acquiring MPI Research should raise Charles Rivers' profits as early as this year and expand its business with biotech.

By Ned Pagliarulo • Feb. 15, 2018

Bioverativ taps new manufacturer as it steps out of Biogen's shadow

The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.

By Jacob Bell • Feb. 15, 2018

Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug

It's a substantial upfront sum to gain access to Nektar's early-stage candidate, reflecting the growing importance of building an edge in combination immunotherapy.

By Ned Pagliarulo • Feb. 14, 2018

Avid sells off cancer assets, transitioning to CDMO

Boston biotech Oncologie will buy Avid's pipeline oncologics, completing the latter company's transition from drugmaker to contract manufacturer. 

By Suzanne Elvidge • Feb. 13, 2018

Roivant and Poxel sign $650M diabetes deal

While Roivant has programs in endocrinology, the licensing pact for imeglimin pulls the Swiss biotech into the diabetes arena.

By Suzanne Elvidge • Feb. 13, 2018

Fewer regs could lower drug costs: White House council

The Council of Economic Advisers also suggested creating an independent agency to oversee the 340B prescription drug program.  

By Les Masterson • Feb. 12, 2018

Allergan picks up Australian biotech Elastagen in $95M deal

Buying Elastagen's tissue repair platform fits with Allergan's "bolt-on" approach to dealmaking and further expands the pharma's medical aesthetics capabilities. 

By Suzanne Elvidge • Feb. 12, 2018

SeaGen, Pieris ink deal for bispecific I/O drugs

For $30 million upfront and $1.2 billion in potential milestones, SeaGen gains the rights to advance three candidates created through the collaboration.

By Jacob Bell • Feb. 9, 2018

Prescribed Reading: Earnings point to restructuring, not M&A

As pharma companies continued to report full-year earnings, the M&A spree has stopped and the focus has shifted to fixing up the pipeline. 

By Lisa LaMotta • Feb. 9, 2018

J&J strikes potential $1B JAK inhibitor deal with Theravance

The biotech will get $100 million upfront and up to $900 million in milestones should J&J opt into the program. 

By Lisa LaMotta • Feb. 7, 2018

Prescribed Reading: Tax changes disappoint, ho-hum earnings

Recent earnings reports shine a light on investor expectations for the tax code changes and M&A in 2018.

By Lisa LaMotta • Feb. 2, 2018

Boehringer strikes Jardiance outcomes deal with Prime PBM

Intense competition in the diabetes drugs market has pushed manufacturers to search for ways to gain an edge, including value-based deals with payers.

By Jacob Bell • Jan. 31, 2018

SeaGen picks up Cascadian in $614M deal

The Seattle biotech is picking up its neighbor to gain a third late-stage asset. 

By Lisa LaMotta • Jan. 31, 2018

Boosted by tax reform, Lilly looking for ways to spend $9B

While the Indianapolis drugmaker didn't drop any hints, executives said the company isn't planning to hold on to the newly unlocked cash for long.

By Ned Pagliarulo • Jan. 31, 2018

How Amazon, JPM and Berkshire could disrupt healthcare (or not)

"News of three corporate giants forming an independent healthcare company proves every business is a healthcare business," said David Vivero, CEO of digital health startup Amino.

By Shannon Muchmore, Daphne Howland & Jeff Byers • Jan. 31, 2018

BridgeBio picks up shelved Novartis drug, kicks off new subsidiary

New BridgeBio subsidiary QED Therapeutics will develop Novartis' infigratinib in cancer and skeletal dysplasias.

By Suzanne Elvidge • Jan. 31, 2018

Pfizer benefits from tax reform, still vague on M&A

The big pharma expects to bring back as much as $24 billion in cash from overseas, but is still mum on how it will be spent.

By Lisa LaMotta • Jan. 30, 2018

Amazon, JPM, Berkshire form independent health company

The corporate giants gave few details, but said the initial aim is to provide U.S. staff with "high-quality and transparent healthcare at a reasonable cost."

By Shannon Muchmore • Jan. 30, 2018

Sanofi snaps up Ablynx after underwhelming Novo bid

In its second deal this year, the French pharma paid $4.8 billion to build its portfolio in rare blood disorders, beating competitor Novo Nordisk to the punch.

By Lisa LaMotta • Jan. 29, 2018

Prescribed Reading: Art of the deal, pharma dines with Trump

Just a few weeks into the year, M&A showed signs of life. Meanwhile, pharma execs schmoozed in Davos and Q4 earnings were all about the art of the deal. 

By Lisa LaMotta • Jan. 26, 2018

Spark deals Novartis ex-US rights to gene therapy for $105M

Licensing out Luxturna to the Swiss pharma will allow Spark to focus on the U.S. market, while giving it additional financial firepower to support commercialization.

By Ned Pagliarulo • Jan. 25, 2018

Celgene's task: Turn its shiny new toys into growth drivers

Acquiring Juno and Impact put a few potential blockbusters in Celgene's pipeline. Now, investors want to know how the big biotech will follow through.

By Jacob Bell • Jan. 25, 2018

Life science M&A volume down 27% last year, PwC finds

Deal value for big pharma was down 56% to $26 billion in 2017.

By Meg Bryant • Jan. 25, 2018

Biogen: No M&A 'frenzy' coming

The drugmaker announced a tiny deal that left investors wanting more, yet CEO Vounatsos didn't tip his hand about potential takeovers.

By Lisa LaMotta • Jan. 25, 2018

Recent M&A: Good buys or just a stopgap?

A new slate of biotech deals has investors feeling both elated and a bit confused.

By Lisa LaMotta • Jan. 23, 2018